We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Committee Unanimously Recommends New Subcutaneous Dose of Rituxan
FDA Committee Unanimously Recommends New Subcutaneous Dose of Rituxan
An FDA advisory committee unanimously voted to recommend approval of Genentech’s new subcutaneous formulation of Rituxan for several blood cancer indications.